From Research at med.fsu.edu Fri May 1 13:23:35 2020 From: Research at med.fsu.edu (Med Research) Date: Fri, 1 May 2020 17:23:35 +0000 Subject: Weekly Funding Opportunities Message-ID: <678887EBDC79FB438BFD062B064C59A401A16C072A@FSUCOM128.med.ad.fsu.edu> REMINDER TO ALL RESEARCHERS: If you are interested to respond to any funding opportunity (internal or external), please notify Med-RA at research at med.fsu.edu. Emergency Awards: Rapid Investigation of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19) (R21 / R01 Clinical Trial Not Allowed) R21 R01 The purpose of this Funding Opportunity Announcement (FOA) is to provide an expedited funding mechanism for research on Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19). NIAID is issuing this FOA in response to the declared public health emergency issued by the Secretary, HHS, for 2019 Novel Coronavirus (COVID-19). Proposals accepted and reviewed (expedited) on a rolling basis. Expires April 30, 2021. Med-RA deadline to receive draft documents: Ten business days before application submission. Lung Cancer Research Foundation: Disparities in Lung Cancer The foundation invites proposals to advance research dedicated to overcoming disparities in lung cancer. Grants of up to $150,000 over two years will be awarded in support of research dedicated to a wide variety of disparities-related topics, including but not limited to the following: gender disparities in lung cancer burden; causes and risk factors for lung cancer among never-smokers; influence of social and biological risk factors on lung cancer outcomes, access to and use of care, and quality of care; genetic and gene-environment interactions; interactions and contributions of multiple factors (e.g., smoking, genetics, environment, societal factors) to disparities in lung cancer outcomes; contribution of healthcare access and quality to disparities in outcomes; and disparities related to other factors such as geography, socioeconomic status, and age. Due May 29, 2020. Med-RA deadline to receive draft documents: May 18. American Heart Association and Enduring Hearts Research Awards in Pediatric Heart Transplantation These awards provide support for investigators who are actively conducting research directly related to improving the life expectancy and quality of life of Pediatric Heart Transplant Recipients. This funding opportunity will further these areas of focus by offering competitive research grants in basic, clinical, population, and/or translational research via Collaborative Sciences Awards. Research Priorities * evidence-based strategies for improving treatment adherence; * early and accurate identification of acute cellular and antibody-mediated rejection and cardiac allograft vasculopathy, including the development of accurate non-invasive methods and strategies for surveillance; * studies on the causes, prevention, and treatment of cardiac allograft vasculopathy; * strategies to improve the viability of donor hearts, * the development of novel immunotherapies by the identification of novel targets, by improving the side-effect profiles of immunotherapies, and/or by improving methods for monitoring the level of immunosuppression. Applications for the development of new technologies that would address any of these priority areas will also be considered. Additional consideration will be given to applications that include clinical research or applications that include feasible clinical translations(s). Letter of intent due June 1, 2020. Med-RA deadline to receive draft documents: May 18. Congressionally Directed Medical Research Programs Multiple Sclerosis Research Program Clinical Trial Award Pre-application (preproposl): June 17, 2020. Invited full application: October 1, 2020. Exploration - Hypothesis Development Award Pre-application (preproposl): June 17, 2020. Invited full application: October 1, 2020. Investigator Initiated Research Award Pre-application (preproposl): June 17, 2020. Invited full application: October 1, 2020. Med-RA deadline to receive preproposal draft documents: June 4. Breast Cancer Research Program Breakthrough Award Levels 1 and 2 Pre-application (letter of intent): September 8, 2020. Application: September 22, 2020. Med-RA deadline to receive letter of intent draft documents: August 25. Breakthrough Award Level 3 Pre-application (preproposal): June 24, 2020. Invited full application: October 6, 2020. Breakthrough Award Level 4 Pre-application (preproposal): June 24, 2020. Invited full application: October 6, 2020. Med-RA deadline to receive preproposal draft documents: June 11. Era of Hope Scholar Award Pre-application (letter of intent): September 8, 2020. Application: September 22, 2020. Confidential letters of recommendation September 25, 2020. Med-RA deadline to receive letter of intent draft documents: August 25. Innovator Award Pre-application (preproposal): June 24, 2020. Invited full application: October 6, 2020. Confidential letters of recommendation October 8, 2020. Transformative Breast Cancer Consortium Award Pre-application (preproposal): June 24, 2020. Invited full application: October 6, 2020. Med-RA deadline to receive preproposal draft documents: June 11. HRSA Rural Residency Planning and Development Program The Health Resources and Services Administration (HRSA) is accepting applications for the fiscal year (FY) 2020 Rural Residency Planning and Development (RRPD) Program. The purpose of this program is to develop newly accredited and sustainable rural residency programs in family medicine, internal medicine, public health and general preventive medicine, psychiatry, general surgery, and obstetrics and gynecology, to support expansion of the physician workforce in rural communities. Rural residency programs are accredited medical residency training programs that primarily train residents in rural training sites for greater than 50 percent of their total time in residency, and focus on producing physicians who will practice in rural communities. One common model is the 1+2 Rural Training Track (RTT), where the first year of training occurs within a larger program, typically in an urban hospital or academic medical center, and the final two years in a rural health facility. The new rural residency programs will: (1) achieve accreditation through the Accreditation Council for Graduate Medical Education (ACGME), (2) ensure sustainability through public or private funding beyond the RRPD period of performance, and (3) track residents? career outcomes post-graduation, including but not limited to retention in rural communities. Funds will support planning and development costs accrued while achieving program accreditation. Hospitals, medical schools and community-based ambulatory settings that have a rural designation along with consortia of urban and rural partnerships are eligible to apply for a grant award. Due June 30, 2020. Med-RA deadline to receive draft documents: June 17. Superfund Research Program Occupational Health and Safety Education Programs on Emerging Technologies (R25 ? Clinical Trial Not Allowed) The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH. The overarching goal of this R25 program is to support educational activities that complement and/or enhance the training of a workforce to meet the nation?s biomedical, behavioral and clinical research needs. To accomplish the stated over-arching goal, this FOA will support creative educational activities with a primary focus on: * Courses for Skills Development * Research Experiences * Curriculum or Methods Development The intent of this announcement is to provide an opportunity to Institutions of Higher Education to develop and offer continuing education courses, research experiences, and academic curricula on occupational health and safety management and laboratory practices in the areas of emerging technologies, emerging contaminants, and/or disaster response. Target participants include industrial hygienists, graduate students, postdoctorates, and professionals involved in the research, evaluation, management, and handling of hazardous substances. The Superfund Research Program also expects that such programs will provide a unique educational opportunity to those professionals involved in the training of other personnel for careers in these new industries. These programs are also meant to expand and complement existing educational programs in occupational health and safety and industrial hygiene. Due August 3, 2020. Med-RA deadline to receive draft documents: July 21. Arena Pharmaceuticals: Arena of Care Award in IBD In an effort to broaden its impact and improve the quality of life for patients with Inflammatory Bowel Disease (IBD), Arena Pharmaceuticals has introduced the Arena of Care Award in IBD, a competitive grant program to support the development and implementation of innovative community-based services and initiatives that address unmet need(s) of those impacted by IBD. Successful proposals for the Arena of Care Award will meet one or more of the following key objectives: increase capacity for innovative programs that address unmet need(s) of the IBD community; increase understanding of IBD through education that shifts perspectives and perceptions to reduce misconceptions and stigma associated with the disease; increase opportunities for IBD stakeholder (e.g., patients, parents/guardians, caregivers) engagement in the development and delivery of IBD education, awareness, and support services; increase health care and service provider awareness of IBD through targeted education and/or training (e.g., IBD information dissemination at primary and specialty HCP offices, outpatient clinics, hospitals, and other community points of care); and reduce disparities in access to IBD health care and support services among patients of diverse ethnic and racial backgrounds, and among other traditionally underserved patient. The annual maximum award amount for an individual organization is $25,000 and $50,000 for collaborative proposals involving two or more organizations). Due August 31, 2020. Med-RA deadline to receive draft documents: August 18. Identifying Innovative Mechanisms or Interventions that Target Multimorbidity and Its Consequences (R01 Clinical Trial Optional) This Funding Opportunity Announcement (FOA) invites applications that seek to support the identification of shared mechanisms and development of innovative interventions to address multimorbidity or multiple chronic conditions (MCCs) and its consequences. Intervention research supported by this initiative should be designed to study: (1) mechanisms or pathways that prevent MCCs, including the identification of early biomarkers, behavioral pathways, and individual and contextual risk factors and interactions that contribute to the development of common MCCs; (2) targeted therapies and management, including self-management, of MCCs to delay progression and prevent onset of new diseases; and (3) innovative health care partnership models for managing or treating MCCs. Studies may include shared mechanisms, and assessments of interactions between risk factors and interventions that address MCCs at different periods of the lifespan in diverse populations. Use of innovative technologies to assess and intervene on risk factors and pathways are encouraged. Studies may also include those that make use of existing data and/or data linkages to explore new research questions that may be helpful in understanding the impact of mechanisms in isolation or in combination. Of particular interest are interventions that target prevention and treatment of multiple chronic health conditions, including study designs that address therapeutic targets for preventing co-occurring MCCs. Standard dates apply. First standard due date is October 5, 2020. Expires September 8, 2023. Med-RA deadline to receive draft documents for October 5 standard date: September 22. Advancing Research to Develop Improved Measures and Methods for Understanding Multimorbidity (R01 Clinical Trial Optional) This Funding Opportunity Announcement (FOA) invites applications that seek to improve the availability, quality, and utility of data and measures that capture multimorbidity or multiple chronic conditions (MCCs) and the methods for analyzing multimorbidity data. Research supported by this initiative should be designed to discover, develop, and/or evaluate MCC measures/tools that reflect the longitudinality and life course diversity of multimorbidity. This includes but is not limited to measures/tools to support basic mechanistic discovery of shared MCC pathways using animal models of MCCs, and identification and initial biological, analytical, and clinical evaluation of MCC shared signatures. Also sought are patient-focused studies that capture patient reports and related constructs such as functional limitations and quality of life; analytic approaches best suited for use with multimorbidity data and matched to target populations; and approaches that fully harness the wealth of multimorbidity data available in EHR systems. Studies may make use of existing data and data linkages to explore new research questions related to co-occurring MCCs. Standard dates apply. First standard due date is October 5, 2020. Expires September 8, 2023. Med-RA deadline to receive draft documents for October 5 standard date: September 22. Mucosal Immunology Studies Team (MIST) (U01 Clinical Trial Not Allowed) The purpose of this Funding Opportunity Announcement (FOA) is to solicit applications from institutions/organizations to participate in a cooperative research group, the Mucosal Immunology Studies Team (MIST), focusing on immune mechanisms and immune regulation at mucosal surfaces of the respiratory, gastrointestinal and urogenital tracts. The main objective of this program is to break new ground in the understanding of basic mucosal immune mechanisms by introducing new ideas, approaches and technologies that address the difficult questions in mucosal immunology. Due October 9, 2020. Med-RA deadline to receive draft documents: September 28. U.S. ? India Collaborative Environmental Health Research Program (R01 Clinical Trial Optional) The purpose of the United States (U.S.)-India Program for Environmental Health Collaborative Research is to stimulate and promote collaborative basic, translational, and clinical research between U.S.-based researchers and Indian researchers and to gain a comprehensive understanding of the impacts of environmental insults on children and adults across all organ systems (e.g. pulmonary, cardiovascular, cancer, and neurological disorders). The National Institute of Environmental Health Sciences (NIEHS) and the Indian Council for Medical Research (ICMR) are interested in supporting collaborative research and research training through joint U.S.-India partnerships that address or seek to understand how exposures to toxic environmental insults alter biologic processes and are linked to disease initiation, progression, or morbidity. In addition, both agencies are interested in research that leads to the development of prevention and intervention strategies to reduce environmentally induced diseases. To promote these collaborative efforts from the outset, the partnering U.S. and Indian investigators must work jointly to submit identical applications to NIH and the Indian Council of Medical Research (ICMR), respectively. Due October 15, 2020. Med-RA deadline to receive draft documents: October 5. To search for additional funding opportunities, please visit CoM?s unofficial funding opportunities blog. -------------- next part -------------- An HTML attachment was scrubbed... URL: From Research at med.fsu.edu Mon May 11 13:14:38 2020 From: Research at med.fsu.edu (Med Research) Date: Mon, 11 May 2020 17:14:38 +0000 Subject: Weekly Funding Opportunities Message-ID: <678887EBDC79FB438BFD062B064C59A401A16C2878@FSUCOM128.med.ad.fsu.edu> When Everyone Strives Foundation: Leukemia Research Grants This request for proposals is offered by the When Everyone Survives Foundation (WES Leukemia Research Foundation) to solicit innovative research in leukemia. Grants of $50,000 for one year are offered to new and established investigators who are requesting support for laboratory, translational, or clinical research related to acute leukemia. The WES Foundation is supports leukemia research because it recognizes that significant advances in the understanding, diagnosis, and treatment of leukemia are needed to achieve the goal of ?When Everyone Survives?. Renewal of initial research support may be considered for one or more additional years based upon productivity. Awardees are required to submit a renewal request 60 days before your award end date. Due June 1, 2020. Med-RA deadline to receive draft documents: May 18. Mark Foundation for Cancer: Emerging Leader Award The Mark Foundation Emerging Leader Awards support innovative research from the next generation of leaders in cancer research. These grants are awarded to outstanding early career investigators to support high-impact, high-risk projects that are distinct from their current research portfolio. $250,000 per year for three years totaling $750,000; indirect costs not to exceed $25,000 per year and are included in total. Eligibility particularities include: * Applicant must be three to eight years from the start of an independent faculty research appointment as of December 31, 2020 (i.e., the official start date of the appointment must fall within the calendar years 2012-2017). Exceptions due to prolonged medical or family leave will be considered on a case-by-case basis. * This award is not intended to be the main source of funding for the applicant?s laboratory. Applicants must therefore demonstrate multi-year independent funding that sustains the central activities of the laboratory (e.g., at least one or two grants such as NIH/R01, NSF/CAREER, or equivalently substantial multi-year awards). Individual eligibility will be determined during the review stage. Letter of intent due June 4, 2020. Med-RA deadline to receive draft documents: May 26. Booz Allen Foundation COVID-19 Innovation Grant The Booz Allen Foundation has established a $1 million Innovation Fund to help nonprofits, entrepreneurs, thought leaders, innovators at colleges and universities, and startups and small businesses harness the power of data, technology, and diverse intellectual capital to improve COVID-19 relief efforts and make a difference. We want to surface the most innovative solutions and empower the individuals and organizations behind those solutions to drive their development and implementation. Nonprofits can apply for grants of up to $100,000. Individuals, teams of individuals, and eligible for-profit organizations can apply for microgrants of up to $10,000. Through the Innovation Fund, the Foundation is specifically targeting solutions and projects that will build lasting community resilience through protecting vulnerable populations and frontline workers or providing for the safe return to work. Due June 5, 2020. Med-RA deadline to receive draft documents: May 26. NIH Research Project Grant (Parent R01) R01 Clinical Trial Not Allowed R01 Clinical Trial Required The NIH Research Project Grant supports a discrete, specified, circumscribed project in areas representing the specific interests and competencies of the investigator(s). The proposed project must be related to the programmatic interests of one or more of the participating NIH Institutes and Centers (ICs) based on their scientific missions. This Funding Opportunity Announcement does not accept applications proposing clinical trial(s). Standard dates apply. Expires May 8, 2023. Med-RA deadline to receive draft documents for June 5, 2020 R01 standard date: May 26. Research Project Grant (Parent R01 Basic Experimental Studies with Humans Required) This Parent Funding Opportunity Announcement is for basic science experimental studies involving humans, referred to in NOT-OD-18-212 as ?prospective basic science studies involving human participants.? These studies fall within the NIH definition of a clinical trial and also meet the definition of basic research. Types of studies that should submit under this FOA include studies that prospectively assign human participants to conditions (i.e., experimentally manipulate independent variables) and that assess biomedical or behavioral outcomes in humans for the purpose of understanding the fundamental aspects of phenomena without specific application towards processes or products in mind. Studies conducted with specific applications toward processes or products in mind should submit under the appropriate ?Clinical Trials Required? or ?Clinical Trial Optional? FOA. The proposed project must be related to the programmatic interests of one or more of the participating NIH Institutes and Centers (ICs) based on their scientific missions. Standard dates apply. Expires May 8, 2023. Med-RA deadline to receive draft documents for June 5, 2020 R01 standard date: May 26. NIH Exploratory/Developmental Research Grant Program (Parent R21 Basic Experimental Studies with Humans Required) The NIH Exploratory/Developmental Grant supports exploratory and developmental research projects by providing support for the early and conceptual stages of these projects. These studies may involve considerable risk but may lead to a breakthrough in a particular area, or to the development of novel techniques, agents, methodologies, models, or applications that could have a major impact on a field of biomedical, behavioral, or clinical research. This Parent Funding Opportunity Announcement is for basic science experimental studies involving humans, referred to inNOT-OD-18-212as ?prospective basic science studies involving human participants.? These studies fall within the NIH definition of a clinical trial and also meet the definition of basic research. Types of studies that should submit under this FOA include studies that prospectively assign human participants to conditions (i.e., experimentally manipulate independent variables) and that assess biomedical or behavioral outcomes in humans for the purpose of understanding the fundamental aspects of phenomena without specific application towards processes or products in mind. Studies conducted with specific applications toward processes or products in mind should submit under the appropriate ?Clinical Trials Required? or ?Clinical Trial Optional? FOA. The proposed project must be related to the programmatic interests of one or more of the participating NIH Institutes and Centers (ICs) based on their scientific missions. Standard dates apply. Expires May 8, 2023. Med-RA deadline to receive draft documents for June 16, 2020 R21 standard date: June 3. NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Required / Clinical Trial Not Allowed) Parent R21 Clinical Trial Required The NIH Exploratory/Developmental Grant supports exploratory and developmental research projects by providing support for the early and conceptual stages of these projects. These studies may involve considerable risk but may lead to a breakthrough in a particular area, or to the development of novel techniques, agents, methodologies, models, or applications that could have a major impact on a field of biomedical, behavioral, or clinical research. This Parent Funding Opportunity Announcement requires that at least 1 clinical trial be proposed. The proposed project must be related to the programmatic interests of one or more of the participating NIH Institutes and Centers (ICs) based on their scientific missions. Applicants should note that some ICs only accept applications proposing mechanistic studies that meet NIH's definition of a clinical trial through this funding opportunity announcement. Parent R21 Clinical Trial Not Allowed The NIH Exploratory/Developmental Grant supports exploratory and developmental research projects by providing support for the early and conceptual stages of these projects. These studies may involve considerable risk but may lead to a breakthrough in a particular area, or to the development of novel techniques, agents, methodologies, models, or applications that could have a major impact on a field of biomedical, behavioral, or clinical research. Standard dates apply. Expires May 8, 2023. Med-RA deadline to receive draft documents for June 16, 2020 R21 standard date: June 3. Management (NIHCM) Foundation Investigator-Initiated Health Services Research Grants NIHCM Foundation supports innovative investigator-initiated research with high potential to inform improvements to the U.S. health care system. Projects must advance the existing knowledge base in the areas of health care financing, delivery, management and/or policy. Letter of inquiry due June 29, 2020. Med-RA deadline to receive draft documents: June 16. Congressionally Directed Medical Research Programs Neurotoxin Exposure Treatment Parkinson's Early Investigator Research Award Pre-application (letter of intent): August 18, 2020. Application: September 16, 2020. Investigator Initiated Research Award Pre-application (letter of intent): August 18, 2020. Application: September 16, 2020. Synergistic Ideal Award Pre-application (letter of intent): August 18, 2020. Application: September 16, 2020. Med-RA deadline to receive draft documents for August 18 letter of intent deadline: August 10. Identifying Innovative Mechanisms or Interventions that Target Multimorbidity and Its Consequences (R01 Clinical Trial Optional) This Funding Opportunity Announcement invites applications that seek to support the identification of shared mechanisms and development of innovative interventions to address multimorbidity or multiple chronic conditions (MCCs) and its consequences. Intervention research supported by this initiative should be designed to study: (1) mechanisms or pathways that prevent MCCs, including the identification of early biomarkers, behavioral pathways, and individual and contextual risk factors and interactions that contribute to the development of common MCCs; (2) targeted therapies and management, including self-management, of MCCs to delay progression and prevent onset of new diseases; and (3) innovative health care partnership models for managing or treating MCCs. Studies may include shared mechanisms, and assessments of interactions between risk factors and interventions that address MCCs at different periods of the lifespan in diverse populations. Use of innovative technologies to assess and intervene on risk factors and pathways are encouraged. Studies may also include those that make use of existing data and/or data linkages to explore new research questions that may be helpful in understanding the impact of mechanisms in isolation or in combination. Of particular interest are interventions that target prevention and treatment of multiple chronic health conditions, including study designs that address therapeutic targets for preventing co-occurring MCCs. Standard dates apply. Expires September 8, 2023. Med-RA deadline to receive draft documents for first standard date deadline October 5, 2020: September 22. Advancing Research to Develop Improved Measures and Methods for Understanding Multimorbidity (R01 Clinical Trial Optional) This Funding Opportunity Announcement invites applications that seek to improve the availability, quality, and utility of data and measures that capture multimorbidity or multiple chronic conditions (MCCs) and the methods for analyzing multimorbidity data. Research supported by this initiative should be designed to discover, develop, and/or evaluate MCC measures/tools that reflect the longitudinality and life course diversity of multimorbidity. This includes but is not limited to measures/tools to support basic mechanistic discovery of shared MCC pathways using animal models of MCCs, and identification and initial biological, analytical, and clinical evaluation of MCC shared signatures. Also sought are patient-focused studies that capture patient reports and related constructs such as functional limitations and quality of life; analytic approaches best suited for use with multimorbidity data and matched to target populations; and approaches that fully harness the wealth of multimorbidity data available in EHR systems. Studies may make use of existing data and data linkages to explore new research questions related to co-occurring MCCs. Standard dates apply. Expires September 8, 2023. Med-RA deadline to receive draft documents for first standard date deadline October 5, 2020: September 22. Large scale mapping and/or molecular profiling of ensembles and/or cell-types mediating opioid action in the rodent brain (R01 ? Clinical Trial Not Allowed) This funding opportunity announcement aims to support research that employs innovative scalable technologies to identify, map, and profile cellular ensembles and/or cell-types that produce and/or respond to opioids or that are engaged during different stages of opioid use (acute, chronic, withdrawal, abstinence, relapse). Emphasis is on approaches that enable high-throughput single-cell resolution mapping, anatomical characterization and/or molecular profiling of cells identified as targets of, or as primary sources of opioids in the brain. Due October 30, 2020. Med-RA deadline to receive draft documents: October 19. To search for additional funding opportunities, please visit CoM?s unofficial funding opportunities blog. -------------- next part -------------- An HTML attachment was scrubbed... URL: From Research at med.fsu.edu Mon May 18 16:23:43 2020 From: Research at med.fsu.edu (Med Research) Date: Mon, 18 May 2020 20:23:43 +0000 Subject: Weekly Funding Opportunities Message-ID: <678887EBDC79FB438BFD062B064C59A401A16C514E@FSUCOM128.med.ad.fsu.edu> Children's Heart Foundation: Congenital Heart Defect Research CHF seeks to fund life-saving, life-changing CHD research in clinical cardiology, basic science, population science, and advancement of surgical/interventional techniques, including, but not limited to the following areas: * Genetics * Biochemistry * Pharmacology * Devices and procedural research (cardiac catheterization and surgery) * Neurodevelopmental and functional outcomes * Quality and policy regarding delivery of care, coverage, and access * Maternal environment and modifiable disease impact on fetuses with CHD * Fetal diagnosis and intervention * Long-term care of adults with CHDs * Technological development and advancements $100,000 for 1-2 year projects, no IDC. Due June 5, 2020. Med-RA deadline to receive draft documents: May 26. Vilcek Prizes For Creative Promise in Biomedical Science Three unrestricted cash prizes of $50,000 each will be awarded to young foreign-born biomedical scientists who demonstrate outstanding early achievement in basic, applied, and/or translational biomedical science. Applicants must have earned a doctoral degree (MD, PhD, or equivalent) and should hold full-time positions at an academic institution or other organization, including positions of assistant or associate professor, or equivalent independent position. To be eligible, applicants must have been born outside the United States; be no older than age 38 as of December 31, 2020 (born on or after January 1, 1982); be a naturalized citizen or permanent resident (green card holder) of the United States; be a holder of an H1B or O-1 visa and have been living and working in the United States for at least five years; or have been granted Deferred Action for Childhood Arrivals (DACA) relief. Due June 10, 2020. Med-RA deadline to receive draft documents: May 28. Neuroendocrine Tumor Research Foundation: Research Grants The Neuroendocrine Tumor Research Foundation (NETRF) is inviting applications for innovative research with the potential to increase the basic understanding of these uncommon tumors and lead to the development of more effective therapies. Grants ranging between $100,000 to $1.2 million will be awarded in support of projects over one to four years in the areas of basic, translational, or clinical neuroendocrine cancer research. Four different grants will be awarded: * Accelerator Award ? Grants of up to $1.2 million over four years will be awarded to projects that bring together investigators from diverse scientific disciplines. * Investigator Awards ? Grants of up to $300,000 over two years will be awarded to investigators and teams with the tools to study neuroendocrine cancers in innovative and transformative ways. * Pilot Awards ? Grants of up to $100,000 over one year will be awarded for pilot studies. * Mentored Awards ? Grants of up to $120,000 over two years will be awarded to encourage early-career investigators to pursue neuroendocrine tumor research and make a commitment to the field. Areas of interest include but are not limited to application of existing or new technologies to target NETs; new/optimized experimental models; cancer metabolism; deciphering the molecular underpinnings of NETs; diagnostics; clinical research, cell invasion and metastasis; immune microenvironment; and nuclear medicine, theranostics, and/or imaging. NETRF also invites proposals that cover promising and potentially transferable technologies that have been applied successfully to other areas of cancer. While NETRF recognizes that neuroendocrine cancers can develop in many different organs, the focus of this RFP includes gastro-entero-pancreatic NETs, including sites of metastasis, and lung carcinoids. Due June 12, 2020. Med-RA deadline to receive draft documents: June 1. Novel, High-Impact Studies Evaluating Health System and Healthcare Professional Responsiveness to COVID-19 (R01) This Funding Opportunity Announcement (FOA) invites R01 grant applications for funding to support novel, high-impact studies evaluating the responsiveness of healthcare delivery systems, healthcare professionals, and the overall U.S. healthcare system to the COVID-19 pandemic. AHRQ is interested in funding critical research focused on evaluating topics such as effects on quality, safety, and value of health system response to COVID-19; the role of primary care practices and professionals during the COVID-19 epidemic; understanding how the response to COVID-19 affected socially vulnerable populations and people with multiple chronic conditions; and digital healthcare including innovations and challenges encountered in the rapid expansion of telehealth response to COVID-19. AHRQ encourages multi-method, rapid-cycle research with the ability to: produce and disseminate initial findings (e.g. observations, lessons learned, or findings) within 6 months after award and then regularly throughout the remainder of the award period. Due June 15, 2020. Med-RA deadline to receive draft documents: June 2. Single Cell Opioid Responses in the Context of HIV (SCORCH) Program Expansion: CNS Data Generation for Chronic Opioid, Methamphetamine, and/or Cocaine Exposures (U01 Clinical Trial Not Allowed) To support generation of single cell RNA-sequencing data sets for at least one brain region relevant to persistent HIV infection and opioid, cocaine and/or methamphetamine use disorder. Due July 20, 2020. Med-RA deadline to receive draft documents: July 7. NINDS Research Program Award (R35, Outstanding Investigator Award, Clinical Trial Optional) The purpose of the NINDS Research Program Award (RPA) is to provide longer-term support and increased freedom and flexibility to Program Directors (PDs)/Principal Investigators (PIs) to allow them to redirect their time away from the administrative burden of writing and managing multiple grant applications and towards engaging in the lab. This RPA affords investigators at most career stages the opportunity to advance their long-term research goals, rigorously explore exciting research opportunities, and mentor trainees, which support and align with the mission of NINDS. RPAs will support the overall research programs of NINDS-funded investigators for up to 8 years, at a level commensurate with a PD/PI?s recent NINDS support (Part 2, Section II). This greater funding stability will provide eligible investigators increased security, allowing them to undertake research projects that require a longer timeframe or to embark upon research that breaks new ground. Research activities outside of the NINDS mission, or traditionally supported by another NIH Institute or Center, will not be considered through this program. Benefits of the RPA include: ? A more stable funding environment, facilitating the pursuit of longer-term research goals; ? Flexible funding, enabling investigators to pursue research opportunities as they arise, not tied to specific aims; ? Reduced time spent writing grant applications and managing multiple grant awards, allowing investigators to spend more time conducting and overseeing research; and ? More time for PDs/PIs to mentor and train individuals in their laboratories. Enhancing the diversity and inclusiveness of the neuroscience and biomedical research workforce will enhance our overall creativity and ability to expand fundamental knowledge about the brain and nervous system and contribute to reducing the burden of neurological disease. The RPA is a signature program for NINDS, as such NINDS strives to ensure it reflects our commitment to diversity. As scientific progress accelerates by leveraging a broad range of experiences, NINDS strongly encourages women and individuals from diverse backgrounds (including nationally underrepresented groups) to apply. Due July 31, 2020. Med-RA deadline to receive draft documents: July 20. NIH Support for Conferences and Scientific Meetings (Parent R13 Clinical Trial Not Allowed) The purpose of the NIH Research Conference Grant (R13) is to support high quality conferences that are relevant to the public health and to the scientific mission of the participating Institutes and Centers. Standard dates apply. Expires May 8, 2023. Med-RA deadline to receive draft documents for August 12 standard date: July 30. HIV Infection of the Central Nervous System (R01 Clinical Trial Not Allowed) The goals of this Funding Opportunity Announcement (FOA) are to stimulate further research on delineating the pathophysiology of HIV-1 associated CNS disease in the setting of chronic viral suppression and ART. In addition, FOA also encourages research studies to aid in the identification/ validation of biomarkers and pre-clinical targets with quantifiable readouts in domestic and international settings. Multidisciplinary research teams and collaborative alliances are encouraged but not required. Standard dates apply. Expires May 8, 2023. Med-RA deadline to receive draft documents for September 7 standard date: August 25. Eradication of HIV-1 from Central Nervous system Reservoirs (R01 Clinical Trial Not Allowed) This Funding Opportunity Announcement invites research grant applications studying mechanisms of HIV-1 persistence and eradication strategies specifically focused on the central nervous system in the context of viral suppression. Basic and translational research in domestic and international settings are of interest. Multidisciplinary research teams and collaborative alliances are encouraged but not required. Standard dates apply. Expires May 8, 2023. Med-RA deadline to receive draft documents for September 7 standard date: August 25. Congressionally Directed Medical Research Programs Hearing Restoration Research Program Focused Research Award Pre-application (prepropsal): July 14, 2020. Application: November 3, 2020. Med-RA deadline to receive draft documents for July 14 preproposal deadline: July 7. Kidney Cancer Research Program Academy of Kidney Cancer Investigators ? Early Career Investigator Award Pre-application (letter of intent): August 5, 2020. Application: August 26, 2020. Med-RA deadline to receive draft documents for August 5 letter of intent deadline: July 27. Concept Award Pre-application (letter of intent): July 15, 2020. Application: August 5, 2020. Med-RA deadline to receive draft documents for July 15 letter of intent deadline: July 6. Translational Research Partnership Award Pre-application (letter of intent): August 5, 2020. Application: August 26, 2020. Med-RA deadline to receive draft documents for August 5 letter of intent deadline: July 6. Prostate Cancer Research Program Prostate Cancer Pathology Resource Network Award Pre-application (letter of intent): September 10, 2020. Application: September 24, 2020. Med-RA deadline to receive draft documents for September 10 letter of intent deadline: August 31. To search for additional funding opportunities, please visit CoM?s unofficial funding opportunities blog. -------------- next part -------------- An HTML attachment was scrubbed... URL: From Research at med.fsu.edu Tue May 19 14:26:52 2020 From: Research at med.fsu.edu (Med Research) Date: Tue, 19 May 2020 18:26:52 +0000 Subject: 5/27 | OCOH Virtual Town Hall: Future of HIV Treatments & Care In-Reply-To: References: Message-ID: <678887EBDC79FB438BFD062B064C59A401A16C5D32@FSUCOM128.med.ad.fsu.edu> Forwarded on behalf of Dr. Jeffrey Joyce. Display problems? View this newsletter in your browser. [https://urldefense.com/v3/__https://phhp-epi-healthstreet-a2.sites.medinfo.ufl.edu/wordpress/files/2015/02/Screen-Shot-2020-05-19-at-12.57.37-PM.png__;!!PhOWcWs!jdUX4o1yH0b7cuK2kLcd933WqKlN-VU5eY_E9JYrHo7mbCYFXV1MkM4nvxvFbGjC3lZmP80xmjxJzKl8_Pw$ ] [https://urldefense.com/v3/__https://phhp-epi-healthstreet-a2.sites.medinfo.ufl.edu/wordpress/files/2015/02/Screen-Shot-2020-04-09-at-6.21.29-PM-2.png__;!!PhOWcWs!jdUX4o1yH0b7cuK2kLcd933WqKlN-VU5eY_E9JYrHo7mbCYFXV1MkM4nvxvFbGjC3lZmP80xmjxJKtqFwjo$ ] [https://urldefense.com/v3/__https://phhp-epi-healthstreet-a2.sites.medinfo.ufl.edu/wordpress/files/2015/02/Screen-Shot-2020-05-15-at-2.06.52-PM.png__;!!PhOWcWs!jdUX4o1yH0b7cuK2kLcd933WqKlN-VU5eY_E9JYrHo7mbCYFXV1MkM4nvxvFbGjC3lZmP80xmjxJ3Oc7EHc$ ] RSVP: https://urldefense.com/v3/__https://bit.ly/HIVFutureRSVP__;!!PhOWcWs!jdUX4o1yH0b7cuK2kLcd933WqKlN-VU5eY_E9JYrHo7mbCYFXV1MkM4nvxvFbGjC3lZmP80xmjxJQ6hiSFk$ Zoom Meeting: https://urldefense.com/v3/__https://ufl.zoom.us/j/91082469319__;!!PhOWcWs!jdUX4o1yH0b7cuK2kLcd933WqKlN-VU5eY_E9JYrHo7mbCYFXV1MkM4nvxvFbGjC3lZmP80xmjxJd7VS71Y$ On Wednesday, May 27th, UF HealthStreet is hosting a virtual Our Community, Our Health (OCOH) interactive town hall focusing on the Future of HIV Treatments & Care. We invite you to join our panel of health professionals as we discuss the future directions of HIV treatments, clinical care interventions, and preventative community health programs. Our panel of experts includes representatives from the University of Florida Division of Infectious Diseases and Global Medicine and College of Nursing. We also welcome perspectives from the Florida State University Center for Translational Behavioral Science and College of Nursing. The panel will answer questions from audience members who join us via livestream! Our panelists include: Robert Lucero, Ph.D, MPH, RN, FAAN, Associate Professor of Nursing, UF Department of Family, Community and Health Systems Science Jennifer Janelle, M.D., Assistant Professor of Medicine, UF Division of Infectious Diseases and Global Medicine Frankie Wong, Ph.D, Professor, Center for Translational Behavioral Science, FSU College of Nursing Nicole Ennis, Ph.D (Moderator), Associate Professor, Department of Behavioral Sciences and Social Medicine, FSU College of Medicine Lara Gadkowski, MD, MPH, MS, Associate Professor of Medicine, UF Division of Infectious Diseases and Global Medicine RSVP NOW! Please share this invitation with your friends and colleagues! Time: 5:00-6:00 P.M. EDT Location: Online via Zoom Meetings RSVP: https://urldefense.com/v3/__https://bit.ly/HIVFutureRSVP__;!!PhOWcWs!jdUX4o1yH0b7cuK2kLcd933WqKlN-VU5eY_E9JYrHo7mbCYFXV1MkM4nvxvFbGjC3lZmP80xmjxJQ6hiSFk$ Zoom Meeting: https://urldefense.com/v3/__https://ufl.zoom.us/j/91082469319__;!!PhOWcWs!jdUX4o1yH0b7cuK2kLcd933WqKlN-VU5eY_E9JYrHo7mbCYFXV1MkM4nvxvFbGjC3lZmP80xmjxJd7VS71Y$ For more information and to view our past OCOH town halls, please visit MyHealthStreet.org [https://urldefense.com/v3/__https://phhp-epi-healthstreet-a2.sites.medinfo.ufl.edu/wordpress/files/2015/02/Footer-Image-1.png__;!!PhOWcWs!jdUX4o1yH0b7cuK2kLcd933WqKlN-VU5eY_E9JYrHo7mbCYFXV1MkM4nvxvFbGjC3lZmP80xmjxJKZ-ybqM$ ] HealthStreet Services HealthStreet is a community engagement program that connects community members to medical and social services and opportunities to participate in health research at the University of Florida. By completing a health assessment with one of our Community Health Workers, we can provide you with information about low or no-cost services, including eye exams, mental health counseling, dance classes, cooking classes, health support groups, and a clothing closet and toiletry pantry. Your voice is important, and you can be heard by becoming a HealthStreet member! Learn More about HealthStreet Would you like to help HealthStreet build community, support students, and continue its groundbreaking research? Make a gift of any amount Click Below to Connect With Us on Facebook and Twitter! [https://urldefense.com/v3/__https://phhp-epi-healthstreet-a2.sites.medinfo.ufl.edu/wordpress/files/2015/02/f_logo_RGB-Hex-Blue_512-1-1.png__;!!PhOWcWs!jdUX4o1yH0b7cuK2kLcd933WqKlN-VU5eY_E9JYrHo7mbCYFXV1MkM4nvxvFbGjC3lZmP80xmjxJ89_-VJQ$ ] [https://urldefense.com/v3/__https://phhp-epi-healthstreet-a2.sites.medinfo.ufl.edu/wordpress/files/2015/02/Twitter_Social_Icon_Circle_Color-1-1-1.png__;!!PhOWcWs!jdUX4o1yH0b7cuK2kLcd933WqKlN-VU5eY_E9JYrHo7mbCYFXV1MkM4nvxvFbGjC3lZmP80xmjxJ705zTh0$ ] Or visit us at MyHealthStreet.org 2401 SW Archer Road, Gainesville, FL 32608 Phone: (352) 294-4880 Questions? Please contact: Jordan Laib Communications Assistant | HealthStreet at the University of Florida College of Public Health and Health Professions | College of Medicine jordanlaib at ufl.edu | (352) 294-4871 [https://urldefense.com/v3/__https://phhp-epi-healthstreet-a2.sites.medinfo.ufl.edu/wordpress/files/2015/02/newsletter-footer.png__;!!PhOWcWs!jdUX4o1yH0b7cuK2kLcd933WqKlN-VU5eY_E9JYrHo7mbCYFXV1MkM4nvxvFbGjC3lZmP80xmjxJZIS8Ce8$ ] Unsubscribe - Edit your subscription -------------- next part -------------- An HTML attachment was scrubbed... URL: From Research at med.fsu.edu Thu May 28 16:00:13 2020 From: Research at med.fsu.edu (Med Research) Date: Thu, 28 May 2020 20:00:13 +0000 Subject: Weekly Funding Opportunities Message-ID: <678887EBDC79FB438BFD062B064C59A401A16C81AF@FSUCOM128.med.ad.fsu.edu> Johnson & Johnson Quickfire Challenge: Maternal Health Of the nearly 700 women who die from pregnancy-related complications per year, the CDC estimates that three in five are preventable and half the injuries could be avoided with proper care. While death and complication rates around the globe are declining, they are rising in the United States, making it the most dangerous place in the developed world to give birth. To address the problem, grants of up to $200,000 will be awarded to innovators in support of ideas aimed at improving pregnancy, birth, and postpartum care for women, making birth safer in the United States and potentially changing the trajectory of health for a lifetime. In addition, awardees will receive access to the global JLABS network and mentorship from experts at the Johnson & Johnson Family of Companies. JLABS has shown a particular interest in the following areas: consumer healthcare; community health approaches; health technologies; medical devices; patient care; pharmaceuticals; and cross-sector Initiatives. Priority will be given to science-based potential innovations backed by data. Due June 19, 2020. Med-RA deadline to receive draft documents: June 8. Congressionally Directed Medical Research Programs Peer Reviewed Alzheimer's Research Program Convergence Science Research Award Pre-application (letter of intent): June 22, 2020. Application: July 21, 2020. Innovation in Care and Support Award Pre-application (letter of intent): June 22, 2020. Application: July 21, 2020. Research Partnership Award Pre-application (letter of intent): June 22, 2020. Application: July 21, 2020. Accelerating Diagnostics for Traumatic Brain Injury Research Award Pre-application (letter of intent): June 22, 2020. Application: July 21, 2020. Leveraging Approaches for Innovation in Care and Support Award Pre-application (letter of intent): June 22, 2020. Application: July 21, 2020. Med-RA deadline to receive draft documents for pre-application due date: June 9. Epilepsy Research Program Idea Development Award Pre-application (letter of intent): June 22, 2020. Application: July 21, 2020. Quality of Life Award Pre-application (letter of intent): June 22, 2020. Application: July 21, 2020. Research Partnership Award Pre-application (letter of intent): June 22, 2020. Application: July 21, 2020. Med-RA deadline to receive draft documents for pre-application due date: June 9. Vision Research Program Focused Translational Team Science Award Pre-application (preproposal): July 28, 2020. Application: November 18, 2020. Investigator Initiated Research Award Pre-application (preproposal): July 28, 2020. Application: November 18, 2020. Translational Research Award Pre-application (preproposal): July 28, 2020. Application: November 18, 2020. Med-RA deadline to receive draft documents for pre-application due date: July 20. NCCIH Natural Product Awards / Cooperative Agreement (R61/R33, R33, U01 Clinical Trial Required) These Funding Opportunity Announcements (FOAs) encourage applications for investigator-initiated, early phase, clinical trials of natural products (i.e., botanicals, dietary supplements, and probiotics) that have a strong scientific premise to justify further clinical testing. Under these FOAs, trials must be designed so that results, whether positive or negative, will provide information of high scientific utility and will support decisions about further development or testing of the natural product. Clinical trials submitted under these FOAs are expected to be hypothesis-based, milestone-driven, and directly related to the research priorities and mission of NCCIH. These FOAs will not support efficacy or effectiveness trials, nor will they support trials to test natural products for the treatment or prevention of cancer. NCCIH Natural Product Early Phase Clinical Trial Phased Innovation Award R61/R33 This FOA will provide up to 3 years (R61 phase) of support for milestone-driven testing of pharmacokinetics, bioavailability, and assessment of the natural product?s effect (i.e., measure of mechanism of action) when used by humans on a biological signature(s). If milestones in the R61 phase are achieved, up to 3 years of additional support (R33 phase) may be awarded to replicate the impact of the natural product on the biological signature(s) when used by humans and assess whether there is an association between the degree of the impact on the biological signature and functional or clinical outcomes in a patient population. Applications are encouraged to design R33 studies to determine how to optimize the impact of the natural product on the biological signature by optimizing the delivery of the natural product by examining different doses or formulation. In addition, applications can be designed to combine the natural product with another treatment approach that is known to impact the same biological signature; or study the impact of the natural product in a target population that is more responsive. This R61/R33 funding mechanism is intended to accelerate the translation of emerging basic science findings about natural products into early-stage clinical testing to determine whether continued clinical research is warranted. A maximum of 5 years will be supported by the two phases of the R61/R33 award. NCCIH Natural Product Early Phase Clinical Trial Award R33 This FOA will provide up to 3 years support for studies to replicate the impact of the natural product on the biological signature(s) when used by humans and assess whether there is an association between the degree of the impact on the biological signature and functional or clinical outcomes in a patient population. Applications are encouraged to design studies to determine how to optimize the impact of the natural product on the biological signature by optimizing the delivery of the natural product by examining different doses or formulations. In addition, applications can be designed to combine the natural product with another treatment approach that is known to impact the same biological signature; or study the impact of the natural product in a target population that is more responsive. This R33 funding mechanism is intended to accelerate the translation of emerging basic science findings about natural products into early stage clinical testing to determine whether continued clinical research is warranted. NCCIH Natural Product Mid Phase Clinical Trial Cooperative Agreement U01 This FOA invites cooperative agreement applications for investigator-initiated mid-phase clinical trials of natural products. All applications submitted under this FOA must be supported by sufficient preliminary data of bioavailability and documentation that the natural product produces a replicable and measurable impact on a biological signature (i.e., measure of the mechanism of action). Only in cases when it is not possible/practical to measure a biological signature in the patient population of interest or when there is a fundamental understanding of the product?s mechanism of action will this preliminary data requirement be waived. Applications submitted to this FOA should propose a mid-phase clinical trial to do the following: determine the optimal dose or formulation of a given natural product for use in a future multi-site clinical trial; or determine which patient phenotypes will be responders versus non-responders to the natural product to inform inclusion/exclusion criteria of a future efficacy study. Due July 20,2020; February 01, 2021; October 01, 2021; June 01, 2022; and February 01, 2023. Med-RA deadline to receive draft documents for July 20, 2020 due date: July 7. NIH Director?s New Innovator Award Program (DP2 Clinical Trial Optional) The NIH Director?s New Innovator Award Program supports early stage investigators of exceptional creativity who propose highly innovative research projects with the potential to produce a major impact on broad, important areas relevant to the mission of NIH. For the program to support the best possible researchers and research, applications are sought which reflect the full diversity of the research workforce. Individuals from diverse backgrounds and from the full spectrum of eligible institutions in all geographic locations are strongly encouraged to apply to this Funding Opportunity Announcement. In addition, applications in all topics relevant to the broad mission of NIH are welcome, including, but not limited to, topics in the behavioral, social, biomedical, applied, and formal sciences and topics that may involve basic, translational, or clinical research. The NIH Director's New Innovator Award Program complements other ongoing efforts by NIH and its Institutes and Centers to fund early stage investigators. The NIH Director?s New Innovator Award Program is a component of the High-Risk, High-Reward Research (HRHR) Program of the NIH Common Fund. Due August 21, 2020. Med-RA deadline to receive draft documents: August 10. NIH Director?s Early Independence Awards (DP5 Clinical Trial Optional) The NIH Director's Early Independence Award supports exceptional junior investigators who wish to pursue independent research soon after completion of their terminal doctoral degree or post-graduate clinical training, thereby forgoing the traditional post-doctoral training period and accelerating their entry into an independent research career. For the program to support the best possible researchers and research, applications are sought which reflect the full diversity of the research workforce. Individuals from diverse backgrounds and from the full spectrum of eligible institutions in all geographic locations are strongly encouraged to apply to this Funding Opportunity Announcement. In addition, applications in all topics relevant to the broad mission of NIH are welcome, including, but not limited to, topics in the behavioral, social, biomedical, applied, and formal sciences and topics that may involve basic, translational, or clinical research. The NIH Director's Early Independence Award is a component of the High-Risk, High-Reward Research program of the NIH Common Fund. Due September 4, 2020. Med-RA deadline to receive draft documents: August 24. NIH Director?s Emergency Early Independence Awards (DP5 Clinical Trial Optional) This FOA solicits applications responsive only to the COVID-19 public health emergency through support of the CARES Act. The NIH Director's Early Independence Award (a component of the High-Risk, High-Reward Research program of the NIH Common Fund) supports exceptional junior investigators who wish to pursue independent research soon after completion of their terminal doctoral degree or post-graduate clinical training, thereby forgoing the traditional post-doctoral training period and accelerating their entry into an independent research career. For the program to support the best possible researchers and research, applications are sought which reflect the full diversity of the research workforce. Individuals from diverse backgrounds and from the full spectrum of eligible institutions in all geographic locations are strongly encouraged to apply to this Funding Opportunity Announcement. Due to the COVID-19 public health emergency, the Common Fund will dedicate funds provided by the CARES Act to support a total of 5-10 Early Independence Awards (through this FOA) or Transformative Research Awards (through RFA-RM-20-020) that bring new, innovative perspectives and approaches to the prevention of, preparation for, or response to coronavirus SARS-CoV-2, domestically or internationally. Any relevant area of coronavirus SARS-CoV-2 research is welcome, including behavioral/social science research, research on health disparities, novel therapeutics, and other related topics. As with all High-Risk, High-Reward Research program applications, innovation may be technological or conceptual. Due September 4, 2020. Med-RA deadline to receive draft documents: August 24. NIH Director?s Pioneer Award Program (DP1 Clinical Trial Optional) The NIH Director?s Pioneer Award Program supports individual scientists of exceptional creativity who propose highly innovative research projects with the potential to produce a major impact on broad, important areas relevant to the mission of NIH. For the program to support the best possible researchers and research, applications are sought which reflect the full diversity of the nation?s research workforce. Individuals from diverse backgrounds and from the full spectrum of eligible institutions in all geographic locations are strongly encouraged to apply to this Funding Opportunity Announcement. In addition, applications in all topics relevant to the broad mission of NIH are welcome, including, but not limited to, topics in the behavioral, social, biomedical, applied, and formal sciences and topics that may involve basic, translational, or clinical research. To be considered pioneering, the proposed research must reflect substantially different scientific directions from those already being pursued in the investigator?s research program or elsewhere. The NIH Director?s Pioneer Award is a component of the High-Risk, High-Reward Research (HRHR) Program of the NIH Common Fund. Due September 11, 2020. Med-RA deadline to receive draft documents: August 31. NIH Director?s Transformative Research Awards (R01 Clinical Trial Optional) The NIH Director?s Transformative Research Award Program supports individual scientists or groups of scientists proposing groundbreaking, exceptionally innovative, original, and/or unconventional research with the potential to create new scientific paradigms, establish entirely new and improved clinical approaches, or develop transformative technologies. For the program to support the best possible researchers and research, applications are sought which reflect the full diversity of the nation?s research workforce. Individuals from diverse backgrounds and from the full spectrum of eligible institutions in all geographic locations are strongly encouraged to apply to this Funding Opportunity Announcement. In addition, applications are welcome in all topics relevant to the broad mission of NIH, including, but not limited to, topics in the behavioral, social, biomedical, applied, and formal sciences and topics that may involve basic, translational, or clinical research. No preliminary data are required. Projects must clearly demonstrate, based on the strength of the logic, a compelling potential to produce a major impact in a broad area of relevance to the NIH. The NIH Director?s Transformative Research Award is a component of the High-Risk, High-Reward Research (HRHR) Program of the NIH Common Fund. Due September 30, 2020. Med-RA deadline to receive draft documents: September 21. NIH Director?s Emergency Transformative Research Awards (R01 Clinical Trial Optional) This FOA solicits applications responsive only to the COVID-19 public health emergency through support of the CARES Act. The NIH Director?s Transformative Research Award Program supports individual scientists or groups of scientists proposing groundbreaking, exceptionally innovative, original, and/or unconventional research with the potential to create new scientific paradigms, establish entirely new and improved clinical approaches, or develop transformative technologies. For the program to support the best possible researchers and research, applications are sought which reflect the full diversity of the nation?s research workforce. Individuals from diverse backgrounds and from the full spectrum of eligible institutions in all geographic locations are strongly encouraged to apply to this Funding Opportunity Announcement. No preliminary data are required. Projects must clearly demonstrate, based on the strength of the logic, a compelling potential to produce a major impact on SARS-CoV-2 prevention, preparation, or response. The NIH Director?s Transformative Research Award is a component of the High-Risk, High-Reward Research (HRHR) Program of the NIH Common Fund. Due to the COVID-19 public health emergency, the Common Fund will dedicate funds provided by the CARES Act to support a total of 5-10 Transformative Research Awards (through this FOA) or Early Independence Awards (through RFA-RM-20-021) that bring new, innovative perspectives and approaches to the prevention of, preparation for, or response to coronavirus SARS-CoV-2, domestically or internationally. Any relevant area of coronavirus SARS-CoV-2 research is welcome, including behavioral/social science research, research on health disparities, novel therapeutics, and other related topics. As with all High-Risk, High-Reward Research program applications, innovation may be technological or conceptual. Due September 30, 2020. Med-RA deadline to receive draft documents: September 21. Joint DMS/NIGMS Initiative to Support Research at the Interface of the Biological and Mathematical Sciences (DMS/NIGMS) This program is designed to support research in mathematics and statistics addressing important questions in the biological and biomedical sciences. Research projects that apply routine mathematical or statistical techniques to solve biological or biomedical problems are not appropriate for this competition, and they may be submitted to NIH through other mechanisms (https://grants.nih.gov/grants/oer.htm). Similarly, mathematical, or statistical research projects that are not tied to any specific biological or biomedical problem should be submitted to the appropriate programs at NSF. Proposals designed to create new software tools based solely on existing models and methods will not be accepted in this competition. Additionally, proposals to create models to characterize and analyze a particular biosystem without novel advances in mathematics or statistics are very low priority for the program, and therefore, submission of such proposals are highly discouraged. Successful proposals are expected to address clearly stated biological/biomedical questions, make a compelling case for and develop innovative mathematical/computational/statistical methods or integrate disparate mathematical/computational/statistical fields, and articulate a well-defined plan for the mathematics or statistics to drive biological/biomedical discovery within the funded period. A direct relationship between a biological/biomedical application and the mathematical/computational/statistical work is required. Research collaborations that include scientists from both the life and mathematical science communities are expected. Proposals from single investigators must provide convincing evidence that the principal investigator has the necessary expertise in both mathematics/statistics and life sciences. While projects from existing collaborations are allowed, we strongly encourage exploratory, high-risk and high-reward Track 1 proposals from new teams of researchers. All proposals in response to this solicitation must be responsive to one or more of the research areas of NIGMS (https://www.nigms.nih.gov/research-areas). Proposals not conforming to these areas will be returned without review. Proposals that are of biological/biomedical nature but not within the scope of NIGMS (such as proposals that focus on a specific disease or physiological system) should be submitted to NIH under the parent FOA (https://grants.nih.gov/grants/guide/pa-files/PA-19-056.html). Due September 18, 2020. Med-RA deadline to receive draft documents: September 8. Elucidating the Role of Nutrition in Care and Development of Preterm Infants (R01 Clinical Trial Optional) This Funding Opportunity Announcement (FOA) invites grant applications that address priority gaps in understanding the role of nutrition in the care and development of preterm infants. Due November 30, 2020. Med-RA deadline to receive draft documents: November 16. To search for additional funding opportunities, please visit CoM?s unofficial funding opportunities blog. -------------- next part -------------- An HTML attachment was scrubbed... URL: